Triptan

SAN DIEGO — Patients who used two or more triptans for migraine faced more acute treatment, more emergency-related hospital visits and higher medical costs compared with those who used one, data show.

SAN DIEGO — A novel, oral therapeutic for treatment of migraine was safe and well-tolerated in single ascending doses in a cohort of healthy adults, according to a speaker at the American Headache Society Annual Scientific Meeting.

DENVER – Most with menstrual migraine utilize only acute treatments, rather than preventive measures, to address their symptoms, according to research presented at the American Academy of Neurology annual meeting.

Among seven classes and 25 individual medications, triptans, ergots and anti-emetics were the most effective acute treatments for individuals with migraine, according to research published in Neurology.

Children born to mothers who used triptans for their migraines during pregnancy did not have a greater risk for ADHD symptoms or diagnosis at 5 years of age, according to a Norwegian registry-based study.

Longer duration of perimenstrual migraine attacks among women with menstrual-related migraine appeared linked to increased recurrence risk and triptan use, according to results of a prospective study published in Neurology.

PHILADELPHIA — The oral calcitonin gene-related peptide antagonist ubrogepant provided better pain relief than triptans in patients with migraine, according to study results presented at the American Headache Society Annual Scientific Meeting.